SCDARIC-33 by Regeneron Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval

SCDARIC-33 is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Refractory Acute Myeloid Leukemia.

May 17, 2024 - 04:00

SCDARIC-33 is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Refractory Acute Myeloid Leukemia.

Read the original article

Tags:

Previous Article

Breaking bonds to form bonds: Rethinking the Chemistry of Cations

Opzelura by Incyte for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lu...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Accenture invests in Earli to advance early cancer detection tech

Accenture invests in Earli to advance early cancer dete...

Aug 21, 2024

PRO-1107 by ProfoundBio Suzhou for Transitional Cell Ca...

Apr 21, 2024

Opinion: BMI as a barrier to orthopedic surgery doesn’t make sense for patient health

Opinion: BMI as a barrier to orthopedic surgery doesn’t...

Jan 16, 2024